Tirzepatide + Glycine
Compounded tirzepatide with glycine as a sterile injectable. A dual GIP/GLP-1 receptor agonist used with diet and activity for weight and glucose support.12
Compounding required for medical necessity.
- Active ingredients
- Tirzepatide
- Form
- Injection
- Route
- Subcutaneous
Are you a prescriber?
Download a compounding order form for this medication with dose options and packaging choices.
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. In the SURMOUNT-1 trial of the branded molecule, once-weekly tirzepatide produced substantial, sustained weight reduction versus placebo when combined with lifestyle measures.1
U.S. prescribing information for approved tirzepatide products describes use with a reduced-calorie diet and increased physical activity, and includes a boxed warning about thyroid C-cell tumors observed in rodents.2
This formulation includes glycine, a conditionally essential amino acid involved in pathways such as glutathione synthesis.4 Glycine is being studied for metabolic roles relevant to obesity and related conditions; lower circulating glycine levels are observed in those settings.3 That literature does not establish that adding glycine makes this compounded product more effective than tirzepatide alone for weight or glucose control.
Connect Wellness compounds this sterile injectable for patient-specific prescriptions when a compounded formulation is medically necessary. It is not an FDA-approved finished drug product. Your clinician sets dose, titration, and monitoring. Common class-related effects can include nausea, vomiting, diarrhea, constipation, and decreased appetite. Discuss personal or family history of medullary thyroid carcinoma or MEN2, pancreatitis risk, and other contraindications before use.
References
- Jastreboff AM et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387, 205-216
“In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight.”
- U.S. Food and Drug Administration (2025). ZEPBOUND (tirzepatide) injection, for subcutaneous use — Prescribing Information. FDA Prescribing Information
- Alves A et al. (2019). Glycine Metabolism and Its Alterations in Obesity and Metabolic Diseases. Nutrients, 11, 1356
“In metabolic disorders associated with obesity, type 2 diabetes, and non-alcoholic fatty liver disease, lower circulating glycine levels have been consistently observed.”
- Wang W et al. (2013). Glycine metabolism in animals and humans: implications for nutrition and health. Amino Acids, 45, 463-477